Effectiveness of chemoradiotherapy for radiation-induced bilateral external auditory canal cancer: A case report and literature review

Head Neck. 2019 Jul;41(7):E113-E119. doi: 10.1002/hed.25728. Epub 2019 Mar 4.

Abstract

Background: Radiation-induced bilateral external auditory canal cancer is an extremely rare disease that has yet to be fully characterized in the clinical literature.

Methods: Herein, we present a case study of a 75-year-old man with radiation-induced bilateral external auditory canal cancer. The patient's medical history included left maxillary cancer that had been treated with chemoradiation 19 years earlier and local recurrence with total maxillectomy 10 years earlier. Intracavitary radiation was delivered to the site of postoperative recurrence 8 years before the current presentation. The patient declined radical surgery for the external auditory canal cancer at this time, and a customized combined modality regimen was thus administered.

Results: There was no recurrence of cancer for 22 months, to date, after completing chemoradiotherapy.

Conclusions: Our finding that radiotherapy can be successfully used for radiation-induced cancer indicates that chemoradiotherapy may be a useful strategy for treating this type of malignancy.

Keywords: bilateral external auditory canal cancer; chemotherapy; radiation-induced cancer; radiotherapy; synchronous.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Squamous Cell / etiology
  • Carcinoma, Squamous Cell / therapy*
  • Cetuximab / administration & dosage
  • Chemoradiotherapy*
  • Cisplatin / administration & dosage
  • Docetaxel / administration & dosage
  • Ear Neoplasms / etiology
  • Ear Neoplasms / therapy*
  • Ear, External / radiation effects*
  • Fluorouracil / administration & dosage
  • Humans
  • Male
  • Maxillary Neoplasms / radiotherapy
  • Neoplasms, Radiation-Induced / therapy*

Substances

  • Docetaxel
  • Cetuximab
  • Cisplatin
  • Fluorouracil